Clinscience International’s parent company – the Neuca Group – has acquired a majority holding in US contract research organization (CRO) Oncobay.
The Warsaw, Poland-based organization acquired a 72.6% stake in Oncobay last week citing a desired to expand its clinical trials business in North America.
The deal also builds on a working relationship Oncobay and Clinscience established in 2020. The CROs have worked on several studies and are jointly advancing several dozen immuno-oncology projects.
Clinscience CEO Tomek Dabrowski cited the collaboration as a driver for the investment, explaining “the unbound dedication to immuno-oncology, tailored solutions, and use of technology and data consistency are elements that tied our organizations right from the beginning.
“Our combined powers, supercharged by complementing competencies, proprietary technologies, and streamlined organizational structure, set the stage for a full-scale global alternative in the clinical research market.”
Cliniscience’s contribution to the partnership is its data management technology and presence in the European clinical trials market.
The expanded arrangement with Tampa, Florida-based OncoBay will enable Clinscience to conduct clinical operations in the US and grants access to the local biotechnology market.
Dabrowski added “it allows us to further expand our abilities in cancer research providing our clients with comprehensive support in their pursuit to develop innovative cancer treatments.”
Oncobay CEO Krystyna Kowalczyk predicted the deal would offer clients improved global reach and improve access to potential study participants.
"The combination of oncology expertise, global footprint, and innovative analytics with in-line data assessment tools create the foundation for a unique organization that aims to accelerate research impacting cancer patients' lives.
“The larger connections to the world-class Patient Access available through the Clinscience European Partner Sites Program distinguish this partnership and our ability to transform clinical research positively."
The investment comes just months after OncoBay reached an agreement to use physIQ’s patient monitoring system.